Compare AbCellera Biologics Inc (ABCL) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Crown Castle International Corp — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Crown Castle International Corp trades at $76.83 (market cap $33.70B). The key difference: Crown Castle International Corp is far larger — about 14.3× AbCellera Biologics Inc's market cap, and Crown Castle International Corp pays a 5.5% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CCI | |
|---|---|---|
Market Cap | $2.35B | $33.70B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $113.91 |
52-Week Low | $2.78 | $74.92 |
Enterprise Value | $1.99B | $63.53B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Crown Castle (CCI) trades at $77.22, up 0.81% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q1 2026 miss but strong beats in prior quarters, while the company transitions to a pure-play U.S. tower focus after divesting its fiber business. Cash flow remains positive, but high debt levels and negative shareholder equity pose challenges. The stock is near its 52-week low, with a consensus price target of $97.33 suggesting significant upside potential.
The outlook for CCI hinges on execution of its strategic refocus and cost reductions. Opportunities include a 5.55% dividend yield and analyst optimism, but risks from elevated leverage and competitive pressures in telecom infrastructure warrant caution. Investor sentiment is divided, with technical indicators signaling near-term weakness despite long-term value arguments from bulls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
